Quantcast

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to

Research paper by Emmanuel E Roilides, Fabianne F Carlesse, Margaret M Tawadrous, Heidi H Leister-Tebbe, Umberto U Conte, Susan S Raber, Robert R Swanson, Jean L JL Yan, Jalal A JA Aram, Flavio F Queiroz-Telles,

Indexed on: 09 Feb '20Published on: 08 Feb '20Published in: The Pediatric infectious disease journal



Abstract

Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.

More like this: